Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREESIA-3: Nipocalimab or IVIG in Pregnancies At Risk of FNAIT
NCT06533098Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of nipocalimab in fetal and neonatal alloimmune thrombocytopenia (FNAIT) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Fetus/Neonate with Outcome of Death or Adjudicated Severe Bleeding or Platelet Count Less Than (<) 30*10^9/L. Started Feb 2025; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
fetal and neonatal alloimmune thrombocytopenia (FNAIT)
Beyond the preview
Go deeper on NCT06533098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533098.